Xarelto Lawsuit Update: Clinical Guidelines Warn Those With End-Stage Kidney Disease

August 26, 2015 – – BloodThinnerHelp.com reports on a new development in Xarelto side effects research. Since its release, Xarelto’s run on the United States blood thinner market has been plagued with many Xarelto lawsuits alleging that the drug causes serious adverse events including the development of blood clots, pulmonary embolism, and uncontrollable internal bleeding. The FDA has since then attached two ‘Black Box’ labels to Xarelto, the most strict warning the organization can hand out to a drug.

Recently, new clinical guidelines have been released in which doctors warn that patients with serious kidney problems should not be taking Xarelto due to the risk of blood clots, stroke, and excess bleeding.

Patients With Kidney Disease Advised to Avoid Xarelto Due To Side Effects:

Established medical groups such as The American College of Cardiology, The American Heart Association, and the Society of Thoracic Surgeons have all worked together to develop treatment guidelines for patients who need to be medicated with blood thinning drugs.

These groups collectively advised that when patients are diagnosed with chronic kidney disease (CKD), “warfarin should be used”. They stressed that warfarin be used in cases where the patient is receiving hemodialysis or those who are in serious stages of kidney failure. While they noted that blood thinners such as Xarelto, rivaroxaban, may be considered for use in patients with moderate to severe CKD, they said that these drugs should not be used in patients with end-stage CKD.

The use of blood thinners in patients with CKD requires doctors to be careful because these patients are at a higher risk of experiencing blood clots and have a higher risk of bleeding complications. This is problematic with Xarelto because when the kidney’s aren’t functioning correctly, they are not capable of processing drugs normally and flushing them totally out of the system. This can potentially result in too much of the drug being in the body at once, therefore increasing the risk even further for an internal bleeding event. For these reasons, Xarelto is not recommended to use with patients who are in stage 5 CKD.

Lack of Antidote Makes Xarelto Side Effects More Dangerous:

When Xarelto was released onto the market in 2011, the manufacturers of the drug, Bayer AG and Johnson&Johnson’s pharmaceutical unit, Jannsen Pharmaceuticals, advertised the drug as an easier alternative to warfarin, with its ‘one size fits all’ method of dosing and the relaxed blood testing and dietary restrictions required for the drug’s success. However, what the manufacturers failed to warn doctors and patients of is the fact that unlike warfarin, Xarelto does not have an antidote to reverse its effects. Because there is no antidote, if a patient taking Xarelto suffers from an internal bleeding event, there is no way to stop the bleeding, leading to an uncontrollable bleeding event and serious injury.

A study completed in 2015 revealed that blood monitoring in patients taking Xarelto would have been very helpful in assessing a patient’s risk for excessive bleeding, despite the manufacturer’s endless claims that this step was not necessary.

For more information about the Xarelto litigation, please direct all inquiries to Marc Goldich via 866-425-8902.

###

Contact BloodThinnerHelp.com:

Marc Goldich
866-425-8902
1500 Walnut Street, 4th Floor, Philadelphia, PA 19102.

ReleaseID: 60003672